MYGN Related Analyst PT Change
-
Mizuho Securities Upgrades Myriad Genetics (MYGN) to Buy
-
Oppenheimer Trims Price Target on Myriad Genetics (MYGN) After Larger price Cut from Noridian
-
Goldman Sachs Downgrades Myriad Genetics (MYGN) to Neutral Following SCOTUS Case
-
Jefferies Raises Numbers on Myriad Genetics (MYGN)
-
Piper Jaffray Upgrades Myriad Genetics (MYGN) to Overweight
-
Dougherty & Co Downgrades Myriad Genetics (MYGN) to Neutral; 2013 Reimbursement Uncertainty
-
Auriga Reiterates a 'Buy' on Myriad Genetics (MYGN); Raising PT on Strong Results
Back to MYGN Stock Lookup
